Screener / SEC EDGAR /CIK 0000896622 /10-K filed Feb 6, 2026, compared with Feb 7, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Materials · Plastics Products

Aptargroup, Inc. ATR

Compare with peers Embed
The 10-K against last year's

119 changes: 19 added, 10 removed, 87 reworded, 3 quiet changes

10-K Feb 6, 2026 vs Feb 7, 2025

10-K 0000896622-26-000007 (Feb 6, 2026) vs 10-K 0000896622-25-000007 (Feb 7, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

52 paragraphs · 7 new · 22 reworded · 1 gone · 10-K Feb 6, 2026 against Feb 7, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 37 · 45% changed Every version of it
Challenges to, or the loss of, our intellectual property rights could have an adverse impact on our ability to compete effectively. Our ability to compete effectively depends, in part, on our ability to protect and maintain the proprietary nature of our owned and licensed intellectual property. We own a large number of patents on our products, aspects of our products, methods of use and/or methods of manufacturing, and we own, or have licenses to use, all of the material trademark and trade name rights used in connection with the packaging, marketing and distribution of our major products. We also rely on trade secrets, know-how and other unpatented proprietary technology. We attempt to protect and restrict access to our intellectual property and proprietary information by relying on the patent, trademark, copyright and trade secret laws of the U.S. and other countries, as well as non-disclosure agreements. However, it may be possible for a third party to obtain our information without our authorization, independently develop similar technologies, or breach a non-disclosure agreement entered into with us. Furthermore, many of the countries in which we operate do not have intellectual property laws that protect proprietary rights as fully as do laws in the U.S. The use of our intellectual property by someone else without our authorization could reduce or eliminate certain of our competitive advantages, cause us to lose sales or otherwise harm our business. The costs associated with protecting our intellectual property rights could also adversely impact our business.
Paragraph 8 · 41% changed Every version of it
Increased global cybersecurity threats and more sophisticated, targeted computer crime, as well as failures or disruptions of our information technology systems, could pose a risk to our operations. Increased global information security threats and more sophisticated, targeted computer crime pose a risk to the confidentiality, availability and integrity of our data, operations and infrastructure, as well as the data of our customers. Our internal information technology systems may also fail or suffer experience security breaches, loss or leakage of data, and or other disruptions, which could disrupt our business or result in and the loss of critical and confidential information. The satisfactory performance, reliability and availability of our technology infrastructure is critical to our ability to access data and applications. Locally hosted IT as data centers are declining applications and shutting down and could result in the inability to host operate our applications without a cloud based solution. business effectively.
Paragraph 21 · 25% changed Every version of it
Global health crises, such as the COVID-19 pandemic, have epidemics and pandemics may adversely affected affect our business, and future developments or other global pandemics could cause adverse effects, which may be material. financial condition and results of operations. Global health crises could have a material impact on our operations our employees and our customer, which could adversely impact our business, financial condition and results of operations. For example, during 2020 the COVID-19 pandemic adversely affected our sales of products to our prescription pharma customers, due to lower incidences of common illnesses and doctors' appointments, and to our travel and retail beauty business and on-the-go beverage customers. Customer demand across all segments may decrease quickly as a result of future developments related to a health crises, including Should such an event happen again in the extent, duration and severity of outbreaks, the availability, adoption and efficacy of approved vaccines and treatments, the length of time future, it takes for normal economic and operating conditions to resume, additional governmental actions that may be taken and/or extended in response to outbreaks, and numerous other uncertainties. Such events may result in business and manufacturing disruption, inventory shortages due to disruptions to our supply chain and distribution channels, delivery delays, increased risk associated with customer payments, increased labor cost and reduced labor availability, and reduced sales and operations, any of which could materially affect our stock price, business prospects, financial condition, results of operations and liquidity.
Paragraph 39 · 25% changed Every version of it
We are also from time Defending against such claims, or initiating legal action to time subject to claims from third parties suggesting that we protect our own rights, may be infringing on their intellectual property rights. If we were held liable for infringement, we could be required to pay damages, obtain licenses or cease making or selling certain products. involve significant legal expenses, operational disruptions, and diversion of management attention. Intellectual property litigation, which could result in substantial cost to us and divert the attention of management, may be necessary to protect our trade secrets or proprietary technology or for us to defend against claimed infringement of the rights of others and to determine the scope and validity of others’ proprietary rights. We may not prevail in any such litigation, and if we are unsuccessful, we may not be able to obtain any necessary licenses on reasonable terms or at all. all or such litigation may result in restrictions on our ability to manufacture or sell certain products or operate product lines. Failure to protect our patents, trademarks and other intellectual property rights, or failure to successfully defend against intellectual property litigation, may have a material adverse effect on our business, consolidated financial condition or results of operations.
Paragraph 4 · 23% changed Every version of it
For example, Russia's Although the continued invasion of Ukraine has created significant regional disruption in addition to global security concerns that together with retaliatory sanctions imposed by the U.S. and other NATO members could have a lasting impact on both regional and global economies. As of December 31, 2024, less than 1% of our consolidated net sales were from Russia and Ukraine; in addition, less than 2% is imported into Russia and Ukraine and therefore the war has not had, and we continue to expect that it would not have had a material direct impact to our consolidated results. However, results, we have experienced indirect impacts on our business, including higher energy and other input costs as well as certain supply chain disruptions, which could materially adversely affect our results of operations and financial condition. In addition, some Aptar products and services are subject to various sanctions regimes, including in the U.S. and the EU, relating to Russia. Although we currently have relevant licenses regarding our products and services, changes in the sanctions regimes without obtaining necessary licenses could adversely affect our operations in Russia and, as a result, our relationship with certain customers.
Paragraph 33 · 23% changed Every version of it
We are exposed to risks from lawsuits and claims, including product liability claims, as well as investigations, audits and other proceedings, which may result in substantial costs and expenses or interruption of our normal business operations. We are subject to a number of lawsuits and claims that arise in the ordinary course of our business, which include infringement, product liability, commercial, employment, tort, business interruption and other litigation. We are also subject to indemnification claims under various contracts. Further, the failure of our products to operate as intended may result in a product liability claim against us. We believe we maintain adequate levels of product liability insurance coverage and robust quality control systems at our facilitates. facilities. However, a product liability claim in excess of our insurance coverage or not covered by existing insurance may materially adversely affect our business, results of operations or cash flows.
Paragraph 10 · 21% changed Every version of it
Increased global cybersecurity threats and more sophisticated, targeted computer crime could pose a risk to our operations. Increased global information security threats and more sophisticated, targeted computer crime pose a risk to the confidentiality, availability and integrity of our data, operations and infrastructure, as well as the data of our customers. The rapid evolution and increased adoption of artificial intelligence technologies may intensify our cybersecurity risks. We continue to assess potential threats, including computer viruses, cyberattacks, ransomware attacks, phishing attacks and other malicious activity, and make investments seeking to reduce the risk of these threats by employing a number of security measures, including employee training, monitoring of our networks and systems, ensuring strong data protection standards including authentication mechanisms are in place and safeguarding our critical information assets.
Paragraph 36 · 21% changed Every version of it
Challenges to, or the loss of, our intellectual property rights could have an adverse impact on our ability to compete effectively. Our ability to compete effectively depends, in part, on our ability to protect and maintain the proprietary nature of our owned and licensed intellectual property. We own a large number of patents on our products, aspects of our products, methods of use and/or methods of manufacturing, and we own, or have licenses to use, all of the material trademark and trade name rights used in connection with the packaging, marketing and distribution of our major products. We also rely on trade secrets, know-how and other unpatented proprietary technology. We attempt to protect and restrict access to our intellectual property and proprietary information by relying on the patent, trademark, copyright and trade secret laws of the U.S. and other countries, as well as non-disclosure agreements. However, it may be possible for a third party to obtain our information without our authorization, independently develop similar technologies, or breach a non-disclosure agreement entered into with us. Furthermore, many For example, in March 2025, we filed a lawsuit against ARS Pharmaceuticals, Inc. and ARS Pharmaceuticals Operations, Inc. alleging that our confidential information and trade secrets were improperly disclosed and used. Refer to Note 13 – Commitments and Contingencies of the countries in which we operate do not have intellectual property laws that protect proprietary rights as fully as do laws in Notes to the U.S. The use of our intellectual property by someone else without our authorization could reduce or eliminate certain of our competitive advantages, cause us to lose sales or otherwise harm our business. The costs associated with protecting our intellectual property rights could also adversely impact our business. Consolidated Financial Statements for additional information.

MD&A

124 paragraphs · 12 new · 42 reworded · 9 gone · 10-K Feb 6, 2026 against Feb 7, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 6 · 50% changed
We reported •Reported net income of $374.5 increased 5% to $392.8 million in 2024 compared and reported earnings per share increased 7% to $284.5 million reported in 2023. $5.89.
Paragraph 41 · 47% changed
Adjusted EBITDA for 2024 increased 2025 decreased approximately 10% 1% to $114.1 $158.8 million compared to $103.7 from $159.9 million in 2023. Our profitability 2024. This decrease was positively impacted by mainly due to the higher sales in 2024 less favorable mix of product sales, including the impact of lower tooling margins, along with operational improvements some supplier disruptions and cost containment initiatives. manufacturing inefficiencies. These improvements more than compensate for a negative resin pass-through impact factors, along with the pass through of $2.3 million. This higher tariff costs, led to our Adjusted EBITDA margin improving from 14.8% declining to 12.1% in 2023 2025 compared to 16.0% during 13.0% in 2024.
Paragraph 23 · 43% changed
Interest expense increased by $3.5 $8.8 million in 2024 2025 to $52.7 million compared to $43.9 million compared to $40.4 million in 2023. 2024. During 2024, 2025, we refinanced more than $370 repaid $125.0 million of private placement debt having an interest rates between 1.2% rate of 3.6% and 3.5% issued a total of $600.0 million in new notes with a fixed interest rate of 4.75%, thus increasing both the amount and entered into a new term loan and revolving credit facility borrowings having current variable the average interest rates between 3.8% and 6.6%. rate of our debt during 2025 compared to 2024.
Paragraph 38 · 39% changed
Reported net sales decreased increased approximately 3% 7% in 2024 2025 to $1.31 billion compared to $1.23 billion compared to $1.27 billion in 2023. Core sales also decreased 3% as there were no material changes 2024. Changes in currency rates or impact from our acquisition of iD SCENT. Approximately half of this decrease comes from lower and acquisitions positively impacted net sales by 2% and 3%, respectively. Therefore, core sales increased 2% compared to the prior year, mainly on stronger tooling sales in 2024. Regionally, rebounding 2025. All regions showed sales in growth during 2025 except North America and Latin America could not compensate for lower European due to weaker indie brand skincare demand. Core sales of our products to the beauty F&F market decreased 8% 4% during 2024 2025 mainly due to the lower tooling sales softer demand for our prestige fragrance technologies and difficult European comparisons to strong growth reported during the prior year. Personal facial skincare products. However, personal care core sales increased 2% as 13% over the prior year on higher sales of our hair care and body and skin care products more than compensated for lower sales of our sun care applications. products. Core sales to the home care markets increased 11% 1% over 2023 2024 on higher demand from our customers selling air care and automotive industrial products.
Paragraph 16 · 38% changed
Our cost of sales (“COS”) as a percentage of net sales decreased increased to 62.8% in 2025 compared to 62.2% in 2024 compared to 63.8% in 2023. Our COS percentage was positively 2024. While all three segments showed revenue growth during 2025, sales within the Pharma and Beauty segments were negatively impacted by an improved a mix of our higher-margin pharma services and product sales lower margin applications compared to the same period in 2023. 2024. We were also benefited from improved negatively impacted by operational performance inefficiencies and cost management initiatives, which more than offset an increase in certain input costs.
Paragraph 32 · 37% changed
Reported net sales increased approximately 8% 6% in 2024 2025 to $1.74 billion compared to $1.64 billion compared to $1.52 billion in 2023. As 2024. While there were was no significant impacts impact from our acquisition during 2025, changes in currency rates or acquisitions, positively impacted net sales by 3%. Therefore, core sales also increased 8% 3% in 2024 2025 when compared to 2023. 2024. Strong core sales volume growth for our drug delivery systems to the prescription drug and active material science solutions markets royalty increases more than compensated for lower tooling sales and pricing adjustments to the consumer health care market. secure longer-term contracts. Core sales of our proprietary drug delivery systems to the prescription drug market increased 15% 5% on continued strong increased demand for our allergic rhinitis, emergency medicine and central nervous system and emergency medicine systems solutions along with higher revenues received from customer royalties. Core sales to the consumer health care market declined 4% 8% as higher demand for our eye care solutions was offset by lower sales of nasal decongestant, nasal saline and cough and cold products due products. Injectables core sales increased 11% driven by robust GLP-1 component sales despite a challenging comparison to the first half of 2024 which experienced a 14% increase in revenues related to a soft 2023-2024 cold and flu season and customer inventory management. The 1% increase in core sales to the injectables market was due primarily to the prior year shutdown of operations for the implementation of our new ERP system, which more than compensated for tooling and service revenues that did not repeat. catch-up period following an enterprise resource planning system implementation. Core sales of our active material science solutions increased 13% mainly on improving 3% as higher demand for our active film and diabetes treatment technologies more than compensated for lower tooling sales and growth due to a large tooling sale in our probiotics, diabetes and oral solid dose applications after a period of destocking. Digital Health currently does not represent a significant percentage of the total Pharma sales. previous year period.
Paragraph 65 · 36% changed
We used $396.7 $331.4 million in cash for investing activities during 2024 2025 compared to $324.5 $396.7 million during 2023. During 2024, approximately $99.1 2024. We spent $270.4 million was utilized to fund the 40% equity investment in Goldrain. Our on capital expenditures, $60.2 million on acquisitions, net of cash acquired and $6.3 million, net for investments in capital projects decreased $35.9 million as spending for several large facility expansions tapered off in 2024. equity securities during 2025. In 2025, 2026, we expect our capital investments to be in the range of $280 $260.0 million to $300 $280.0 million.
Paragraph 52 · 36% changed
We present earnings before net interest and taxes (“EBIT”) and (“EBIT”), earnings before net interest, taxes, depreciation and amortization (“EBITDA”). (“EBITDA”) and adjusted earnings per share. We also present our adjusted earnings before net interest and taxes (“Adjusted EBIT”) and EBIT”), adjusted earnings before net interest, taxes, depreciation and amortization (“Adjusted EBITDA”), both EBITDA”) and adjusted earnings per share, all of which exclude restructuring initiatives, acquisition-related costs, purchase accounting adjustments related to acquisitions and investments and investments, net unrealized investment gains and losses related to observable market price changes on equity securities. securities and other special items. For the year ended December 31, 2025, “other special items” include costs incurred related to non-ordinary-course litigation, specifically: lawsuits between Aptar and ARS Pharmaceuticals, Inc. involving Aptar’s claims of trade-secret misappropriation and contractual breaches and ARS’s counterclaims under U.S. antitrust laws; and patent infringement actions filed by Nemera La Verpillière SAS in Germany and France relating to certain of Aptar’s ophthalmic products. These costs are excluded because they do not reflect our core operating performance. Please refer to "Legal Proceedings" within Note 13 - Commitments and Contingencies of the Notes to the Consolidated Financial Statements for additional information. Our Operations Outlook is also provided on a non-U.S. GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of our routine activities, such as restructuring initiatives and acquisition-related costs.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

MD&A209 words changed in this paragraph; it is 54% similar to last year's version.
Reported net sales increased approximately 8% 6% in 2024 2025 to $1.74 billion compared to $1.64 billion compared to $1.52 billion in 2023. As 2024. While there were was no significant impacts impact from our acquisition during 2025, changes in currency rates or acquisitions, positively impacted net sales by 3%. Therefore, core sales also increased 8% 3% in 2024 2025 when compared to 2023. 2024. Strong core sales volume growth for our drug delivery systems to the prescription drug and active material science solutions markets royalty increases more than compensated for lower tooling sales and pricing adjustments to the consumer health care market. secure longer-term contracts. Core sales of our proprietary drug delivery systems to the prescription drug market increased 15% 5% on continued strong increased demand for our allergic rhinitis, emergency medicine and central nervous system and emergency medicine systems solutions along with higher revenues received from customer royalties. Core sales to the consumer health care market declined 4% 8% as higher demand for our eye care solutions was offset by lower sales of nasal decongestant, nasal saline and cough and cold products due products. Injectables core sales increased 11% driven by robust GLP-1 component sales despite a challenging comparison to the first half of 2024 which experienced a 14% increase in revenues related to a soft 2023-2024 cold and flu season and customer inventory management. The 1% increase in core sales to the injectables market was due primarily to the prior year shutdown of operations for the implementation of our new ERP system, which more than compensated for tooling and service revenues that did not repeat. catch-up period following an enterprise resource planning system implementation. Core sales of our active material science solutions increased 13% mainly on improving 3% as higher demand for our active film and diabetes treatment technologies more than compensated for lower tooling sales and growth due to a large tooling sale in our probiotics, diabetes and oral solid dose applications after a period of destocking. Digital Health currently does not represent a significant percentage of the total Pharma sales. previous year period.

Source: Item 7, 10-K 0000896622-26-000007 vs Item 7, 10-K 0000896622-25-000007

Risk Factors170 words changed in this paragraph; it is 48% similar to last year's version.
We are exposed to risks from lawsuits and claims, including product liability claims, as well as investigations, audits and other proceedings, which may result in substantial costs and expenses or interruption of our normal business operations. We are subject to a number of lawsuits and claims that arise in the ordinary course of our business, which include intellectual property infringement, product liability, commercial, employment, tort, business interruption and other litigation. We are also subject For example, in May 2025, Nemera filed patent infringement actions against us in France and Germany relating to indemnification claims under various contracts. Further, the failure certain of our products ophthalmic products. In October 2025, an EPO hearing invalidated Nemera’s main patent claim while allowing an amended claim to operate as intended may result continue. In addition, in a product liability claim September 2025, ARS Pharmaceuticals Operations, Inc. filed an antitrust lawsuit against us. We believe we maintain adequate levels us in the United States District Court for the Southern District of product liability insurance coverage California, alleging violations of U.S. competition laws related to supply of certain components and robust quality control systems at our facilitates. However, a product liability claim in excess are seeking injunctive relief and damages. Refer to Note 13 – Commitments and Contingencies of our insurance coverage or not covered by existing insurance may materially adversely affect our business, results of operations or cash flows. the Notes to the Consolidated Financial Statements for additional information regarding these actions

Source: Item 1A, 10-K 0000896622-26-000007 vs Item 1A, 10-K 0000896622-25-000007

Accounting Policies87 words changed in this paragraph; it is 76% similar to last year's version.
Management believes goodwill in purchase transactions has continuing value. Goodwill is not amortized and must be tested annually, or more frequently as circumstances dictate, for impairment. The annual goodwill impairment test may first consider qualitative factors to determine whether it is more likely than not (i.e., greater than 50 percent chance) that the fair value of a reporting unit is less than its book value. This is sometimes referred to as the “step zero” approach and is an optional step in the annual goodwill impairment analysis. Management has performed this qualitative assessment as of October 1, 2024 2025 over all reporting units with the exception of Beauty and October 1, 2023 for each of our reporting units. Due to the realignment of the Beauty and Closures segments, management determined it appropriate to calculate the fair value of both 2024 over all reporting units with the exception of Injectables and compare with their associated carrying amounts as of January 1, 2023. Other Pharma. As we performed our annual goodwill impairment assessment, due to events or circumstances that were unfavorable for injectables, and the passage of time from our prior Step 1 analysis over the other pharma reporting unit, Beauty segment, management determined it appropriate to calculate the Step 1 fair value of both the Beauty reporting units unit and compare with their its associated carrying amounts amount as of October 1, 2024. 2025.

Source: Item 8, Note 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, 10-K 0000896622-26-000007 vs Item 8, Note 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, 10-K 0000896622-25-000007

Legal Proceedings66 words changed in this paragraph; it is 74% similar to last year's version.
In the normal course of business, we We are subject to a number of lawsuits and claims both actual and potential in nature. While nature including those involving intellectual property and commercial disputes. For example, we are involved in legal proceedings in certain jurisdictions related to alleged infringement of intellectual property rights, alleged customer breach of confidentiality obligations, alleged customer misuse of proprietary information and alleged violations of competition and antitrust laws. We are actively litigating our interests in these matters and management believes the resolution of these claims and lawsuits will not have a material adverse effect on our financial position, results of operations or cash flows, claims and legal proceedings are subject to inherent uncertainties, and unfavorable outcomes could occur that could include amounts in excess of any accruals which management has established. Were such unfavorable final outcomes to occur, it is possible that they could have a material adverse effect on our financial position, results of operations and cash flows.

Source: Item 3, via Note 13 – COMMITMENTS AND CONTINGENCIES, 10-K 0000896622-26-000007 vs Item 3, via Note 13 – COMMITMENTS AND CONTINGENCIES, 10-K 0000896622-25-000007

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of ATR's Risk Factors and MD&A, 10-K Feb 6, 2026 against 10-K Feb 7, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
The rapid evolution and increased adoption of artificial intelligence technologies may intensify our cybersecurity risks. In addition, as locally hosted information technology environments and data centers continue to decline or are decommissioned,we may increasingly rely on cloud-based solutions to host applications and data. Any disruption, failure or security incident affecting our internal systems or our third-party or cloud-based service providers could result in the inability to host or access applications, loss of critical or confidential information, or interruptions to our operations.
Read it in 10-K Feb 6, 2026 at sec.gov
AddedRisk Factors
A material failure or disruption at one or more of our manufacturing facilities could adversely affect our ability to generate sales and meet customer demand. Our ability to generate sales and meet customer demand depends on the continued operation of our manufacturing facilities, many of which involve complex, specialized, and highly regulated manufacturing environments, including clean-room operations. A material failure or disruption at one or more of these facilities could occur for a variety of reasons, including significant equipment or mechanical failures, information technology or systems outages, cybersecurity incidents, power interruptions, fires, explosions, natural disasters, extreme weather events, labor disruptions, public health events, or other causes beyond our control.
Read it in 10-K Feb 6, 2026 at sec.gov
AddedRisk Factors
If operations at any of our manufacturing facilities were materially disrupted, our ability to produce and deliver products to customers could be adversely affected for a period of time. Interruptions in manufacturing could result in lost sales, delayed customer deliveries or product launches, and damage to customer relationships. Manufacturing disruptions could also increase our costs due to production inefficiencies, inventory losses or write-offs, expedited shipping, or the need to transfer production to other facilities or rely on third-party manufacturers, which may be subject to capacity constraints, regulatory requirements, or higher costs.
Read it in 10-K Feb 6, 2026 at sec.gov
AddedRisk Factors
Certain of our products, components, tools, machines, or molds are manufactured at a limited number of facilities or rely on specialized equipment or processes, which may not be easily or quickly replaced. In addition, in the pharmaceutical industry, manufacturing disruptions may be particularly difficult to remediate due to regulatory requirements, validation processes, and customer qualification timelines, which could extend the duration and impact of any disruption.
Read it in 10-K Feb 6, 2026 at sec.gov
AddedRisk Factors
We are exposed to risks from lawsuits and claims, including product liability claims, as well as investigations, audits and other proceedings, which may result in substantial costs and expenses or interruption of our normal business operations. We are subject to a number of lawsuits and claims that arise in the ordinary course of our business, which include intellectual property infringement, product liability, commercial, employment, tort, business interruption and other litigation. For example, in May 2025, Nemera filed patent infringement actions against us in France and Germany relating to certain of our ophthalmic products. In October 2025, an EPO hearing invalidated Nemera’s main patent claim while allowing an amended claim to continue. In addition, in September 2025, ARS Pharmaceuticals Operations, Inc. filed an antitrust lawsuit against us in the United States District Court for the Southern District of California, alleging violations of U.S. competition laws related to supply of certain components and are seeking injunctive relief and damages. Refer to Note 13 – Commitments and Contingencies of the Notes to the Consolidated Financial Statements for additional information regarding these actions
Read it in 10-K Feb 6, 2026 at sec.gov
AddedRisk Factors
We are also from time to time subject to claims from third parties suggesting that we may be infringing on their intellectual property rights. For example, in May 2025, Nemera filed patent infringement actions against us in France and Germany relating to certain of our ophthalmic products. In October 2025, an EPO hearing invalidated Nemera’s main patent claim while allowing an amended claim to continue. Refer to Note 13 – Commitments and Contingencies of the Notes to the Consolidated Financial Statements for additional information.
Read it in 10-K Feb 6, 2026 at sec.gov
RemovedRisk Factors
Consolidation of our customer base could impact our business. We believe mergers and acquisitions within our customer base create opportunities for increasing sales due to the breadth of our product line, our international presence and our long-term relationships with certain customers. However, consolidation of our customers could lead to pricing pressures, concentration of credit risk and fewer opportunities to introduce new products to the market.
Read it in 10-K Feb 7, 2025 at sec.gov
Show the other 48
RewordedRisk Factors
In January 2025, during the initial days of President Trump's second term, the U.S. announced the imposition government imposed a series of additional substantial tariffs on a broad range of imports from various countries, including China, Canada and Mexico, and the subject countries indicated their intention to impose counter measures. Mexico.
Read it in 10-K Feb 6, 2026 at sec.gov
RewordedRisk Factors
The Our internal information technology systems may also fail or experience security breaches, loss or leakage of data, or other disruptions, and the satisfactory performance, reliability and availability of our technology infrastructure is critical to our ability to access data and applications. applications and to operate our business effectively.
Read it in 10-K Feb 6, 2026 at sec.gov
RewordedRisk Factors
We continue to invest internally in several capacity expansions, if If our acquisition integration efforts, including unlocking synergies, are unsuccessful or if our capacity expansions do not provide the expected returns, we may not realize the full potential of the acquisitions and/or investments and as a result our financial performance may suffer.
Read it in 10-K Feb 6, 2026 at sec.gov
RewordedRisk Factors
It is possible that customers may be unable to meet their obligations on a timely basis or may contest their contractual obligations to us under bankruptcy laws or otherwise. otherwise which could adversely affect our ability to collect receivables.
Read it in 10-K Feb 6, 2026 at sec.gov
RewordedRisk Factors
If the customer’s pharmaceutical product is not approved by regulatory bodies or it is not successful on the market, the associated costs we may not be recovered. achieve a future return on the time and effort invested in the development of the product.
Read it in 10-K Feb 6, 2026 at sec.gov
RewordedRisk Factors
We may not prevail in any such litigation, and if we are unsuccessful, we may not be able to obtain any necessary licenses on reasonable terms or at all. all or such litigation may result in restrictions on our ability to manufacture or sell certain products or operate product lines.
Read it in 10-K Feb 6, 2026 at sec.gov
RewordedRisk Factors
We expect the market for our products to remain competitive, as consolidation and/or changing of ownership among our competitors and key customers are increasing in the current economic climate. competitive.
Read it in 10-K Feb 6, 2026 at sec.gov
RewordedRisk Factors
In addition, these matters could lead to increased operating costs or interruptions of our normal business operations. operations or could result in restrictions on our ability to manufacture or sell certain products or operate specific product lines.
Read it in 10-K Feb 6, 2026 at sec.gov
RewordedRisk Factors
However, Although the continued invasion of Ukraine by Russia has not had a material direct impact to our consolidated results, we have experienced indirect impacts on our business, including higher energy and other input costs as well as certain supply chain disruptions, which could materially adversely affect our results of operations and financial condition.
Read it in 10-K Feb 6, 2026 at sec.gov
RewordedRisk Factors
If implemented, such Such tariffs and countermeasures could increase have increased the cost of certain raw materials and components used in our packaging solutions, and have the potential to disrupt our global supply chain and create additional operational challenges.
Read it in 10-K Feb 6, 2026 at sec.gov
RewordedRisk Factors
Such events Should such an event happen again in the future, it may result in business and manufacturing disruption, inventory shortages due to disruptions to our supply chain and distribution channels, delivery delays, increased risk associated with customer payments, increased labor cost and reduced labor availability, and reduced sales and operations, any of which could materially affect our stock price, business prospects, financial condition, results of operations and liquidity.
Read it in 10-K Feb 6, 2026 at sec.gov
Quiet changesRisk Factors
If Therefore, if we are unable to collect upon our accounts receivable as they come due in an efficient and timely manner, our business, financial condition or results of operations may be materially adversely affected.
Read it in 10-K Feb 6, 2026 at sec.gov
AddedMD&A
Net other income increased $25.9 million to $43.1 million in 2025 compared to $17.2 million in 2024. On July 28, 2025, we executed our call option to purchase an additional 31% equity interest in BTY. As a result of this additional investment, we remeasured our previously held minority equity interest in BTY at fair value resulting in a gain of $26.5 million. We also realized approximately $7.3 million in higher equity results from affiliates, which was partially offset by a $2.2 million lower remeasurement gain on our investment in PureCycle.
Read it in 10-K Feb 6, 2026 at sec.gov
AddedMD&A
The reported effective tax rate for 2025 and 2024 was 20.1% and 20.3%, respectively. The tax rate for 2025 reflects a more favorable mix of earnings including a benefit related to the gain resulting from the remeasurement of equity investments to fair value upon becoming the majority equityholder.
Read it in 10-K Feb 6, 2026 at sec.gov
AddedMD&A
Operations that sell proprietary dispensing systems, drug delivery systems, sealing solutions and services to the prescription drug, consumer health care, injectables, active material science solutions and digital health markets form our Pharma segment.
Read it in 10-K Feb 6, 2026 at sec.gov
AddedMD&A
Operations that sell dispensing closures, sealing solutions and food service trays to the food, beverage, personal care, home care, beauty and other markets form our Closures segment. Our food protection business and elastomeric flow-control technology business report through the Closures segment.
Read it in 10-K Feb 6, 2026 at sec.gov
AddedMD&A
Corporate & Other expenses in 2025 increased slightly to $67.8 million compared to $67.5 million of expense in 2024. Higher compensation costs in 2025 were mostly offset by the improved performance of certain equity method investments and lower costs to evaluate acquisition targets when compared to 2024.
Read it in 10-K Feb 6, 2026 at sec.gov
AddedMD&A
Reconciliation of Adjusted Earnings Per Diluted Share For The Year Ended December 31, 2025 December 31, 2024 Income before Income Taxes $ 491,378 $ 469,765 Adjustments: Restructuring initiatives 9,837 13,002 Curtailment gain related to restructuring initiatives (115) (1,851) Net investment loss (gain) 483 (1,713) Gain from remeasurement of equity method investment (26,518) — Transaction costs related to acquisitions 1,460 140 Purchase accounting adjustments related to acquisitions and investments 1,793 — Other special items 8,360 — Foreign currency effects (1) 14,523 Adjusted Earnings before Income Taxes $ 486,678 $ 493,866 Provision for Income Taxes $ 98,881 $ 95,587 Adjustments: Restructuring initiatives 2,503 3,397 Curtailment gain related to restructuring initiatives (30) (478) Net investment loss (gain) 118 (420) Gain from remeasurement of equity method investment — — Transaction costs related to acquisitions 393 35 Purchase accounting adjustments related to acquisitions and investments 282 — Other special items 2,048 — Foreign currency effects (1) 2,955 Adjusted Provision for Income Taxes $ 104,195 $ 101,076 Net Loss Attributable to Noncontrolling Interests $ 206 $ 363 Net Loss Attributable to Redeemable Noncontrolling Interests $ 86 $ — Net Income Attributable to AptarGroup, Inc. $ 392,789 $ 374,541 Adjustments: Restructuring initiatives 7,334 9,605 Curtailment gain related to restructuring initiatives (85) (1,373) Net investment loss (gain) 365 (1,293) Gain from remeasurement of equity method investment (26,518) — Transaction costs related to acquisitions 1,067 105 Purchase accounting adjustments related to acquisitions and investments 1,511 — Other special items 6,312 — Foreign currency effects (1) 11,568 Adjusted Net Income Attributable to AptarGroup, Inc. $ 382,775 $ 393,153 Average Number of Diluted Shares Outstanding 66,725 67,691 Net Income Attributable to AptarGroup, Inc. Per Diluted Share $ 5.89 $ 5.53 Adjustments: Restructuring initiatives 0.11 0.15 Curtailment gain related to restructuring initiatives — (0.02) Net investment loss (gain) 0.01 (0.02) Gain from remeasurement of equity method investment (0.40) — Transaction costs related to acquisitions 0.02 — Purchase accounting adjustments related to acquisitions and investments 0.02 — Other special items 0.09 — Foreign currency effects (1) — 0.17 Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share $ 5.74 $ 5.81
Read it in 10-K Feb 6, 2026 at sec.gov
AddedMD&A
On November 20, 2025, we issued $600.0 million in aggregate principal amount of 4.75% Senior Notes due March 2031 in an underwritten public offering. The form and terms of the notes were established pursuant to an Indenture, dated as of March 7, 2022, as amended and supplemented by a Second Supplemental Indenture, dated as of November 20, 2025, each between the Company and U.S. Bank Trust Company, National Association, as trustee. Interest is payable semi-annually in arrears. The notes are unsecured obligations and rank equally in right of payment with our other existing senior, unsecured indebtedness.
Read it in 10-K Feb 6, 2026 at sec.gov
AddedMD&A
Management applied judgment in determining the fair value of the acquired assets with respect to the acquisitions of Sommaplast and BTY. The judgments made in determining the estimated fair value assigned to the assets acquired, as well as the estimated life of the assets, can materially impact net income in the periods subsequent to the acquisition through depreciation and amortization. In particular, judgment was applied with respect to determining the fair value of acquired technology, trademarks and customer relationships intangible assets, which involved the use of estimates and significant assumptions with respect to the timing and amounts of cash flow projections, the revenue growth rates, the customer attrition rates, the EBITDA margins and the discount rate. Unanticipated events and circumstances may occur, which may affect the accuracy or validity of such assumptions or estimates.
Read it in 10-K Feb 6, 2026 at sec.gov
RemovedMD&A
Net other income increased $5.9 million to $17.2 million in 2024 compared to $11.2 million in 2023. Interest income increased by $7.7 million due to increased cash flow generated from operations and therefore higher interest earned on cash deposits. This increase, along with the $0.3 million increase due to changes in the fair value of our PureCycle investment, more than compensated for the $2.1 million lower contribution from our equity results from affiliates.
Read it in 10-K Feb 7, 2025 at sec.gov
RemovedMD&A
The reported effective tax rate for 2024 and 2023 was 20.3% and 24.2%, respectively. The tax rate for 2024 was lower compared to 2023 due primarily to the realization of deferred tax assets in Luxembourg which were previously not recognized as well as increased tax benefits from stock-based compensation.
Read it in 10-K Feb 7, 2025 at sec.gov
RemovedMD&A
In thousands, except percentages APTAR CLOSURES SEGMENT Year Ended December 31, 2024 2023 % Change 2024 vs. 2023 Net Sales $ 714,008 $ 698,760 2.2% Adjusted EBITDA (1) 114,142 103,693 10.1 Adjusted EBITDA margin (1) 16.0 % 14.8 %
Read it in 10-K Feb 7, 2025 at sec.gov
RemovedMD&A
Corporate & Other expenses in 2024 increased to $67.5 million compared to $62.3 million of expense in 2023. Our 2024 results include approximately $2.2 million of foreign currency gains while 2023 includes approximately $4.2 million of realized gains on sales of PCT shares. The remaining cost increases during 2024 include $3.4 million of costs to evaluate potential acquisition targets, along with some higher professional fees for corporate projects and higher incentive compensation costs.
Read it in 10-K Feb 7, 2025 at sec.gov
RemovedMD&A
Management applied judgment in determining the fair value of the acquired assets with respect to the acquisitions of iD SCENT and Gulf Closures, including the fair values of acquired intangibles including acquired technology, trademarks and customer relationships. In particular, judgment was applied with respect to determining the fair value of acquired technology, trademarks and customer relationships intangible assets, which involved the use of benchmarking to prior deals to assess the reasonableness of allocation of excess purchase price to goodwill and intangibles.
Read it in 10-K Feb 7, 2025 at sec.gov
RewordedMD&A
Restructuring initiatives 13,002 589 8,041 3,835 537 9,837 1,080 4,469 3,566 722 Curtailment gain related to restructuring initiatives (1,851) (115) — — (1,851) (115) — Net investment gain loss (1) (1,713) (1,713) 483 483 Gain from remeasurement of equity method investment (26,518) — (26,518) — — Transaction costs related to acquisitions 140 1,460 952 508 — 140 — Purchase accounting adjustments related to acquisitions and investments 1,793 70 1,723 — — Other special items 8,360 8,360 — — — Adjusted earnings before income taxes 479,343 447,942 76,978 56,816 (70,596) (31,797) 486,678 471,535 67,705 59,761 (71,262) (41,061) Interest expense 43,898 43,898 52,737 52,737 Interest income (12,101) (12,101) (11,676) (11,676) Adjusted earnings before net interest and taxes (Adjusted EBIT) 511,140 447,942 76,978 56,816 (70,596) 527,739 471,535 67,705 59,761 (71,262) — Depreciation and amortization 263,784 120,429 82,931 57,326 3,098 287,363 136,111 91,066 56,716 3,470 — Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) $ 774,924 815,102 $ 568,371 607,646 $ 159,909 158,771 $ 114,142 116,477 $ (67,498) (67,792) $ — Reported net income margin (Reported net income / Reported Net Sales) 10.4 % Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) 21.6 % 34.6 35.0 % 13.0 12.1 % 16.0 %
Read it in 10-K Feb 6, 2026 at sec.gov
RewordedMD&A
During 2024, 2025, we paid $114.1 $120.8 million of dividends, purchased $68.6 $365.0 million of our common stock that was placed into treasury stock stock, received $600.2 million in proceeds from long-term debt obligations, primarily from our note issuance, repaid $166.6 million of long-term debt primarily related to private placement notes and received proceeds of $54.8 $18.9 million on stock option exercises.
Read it in 10-K Feb 6, 2026 at sec.gov
RewordedMD&A
Year Ended December 31, 2024 2025 Prescription Drug (2) Consumer Health Care Injectables Active Material Science Solutions Digital Health Total Reported Net Sales Growth 15% (3)% 1% 13% 37% 8% (5)% 14% 4% 6% Currency Effects (1) —% (3)% (3)% (3)% (1)% —% —% 1% —% (3)% Acquisitions —% —% —% —% —% —% Core Sales Growth 15% (4)% 1% 13% 38% 8% 5% (8)% 11% 3% 3%
Read it in 10-K Feb 6, 2026 at sec.gov
RewordedMD&A
Year Ended December 31, 2024 2025 F&F (2) Personal Care Beauty Home Care Total Reported Net Sales Growth 1% (8)% 10% (3)% 2% 14% 15% 7% Currency Effects (1) (2)% (2)% (1)% (2)% Acquisitions (4)% 1% —% 1% —% Acquisitions —% —% —% —% (13)% (3)% Core Sales Growth (4)% 13% 1% 2% (8)% 11% (3)%
Read it in 10-K Feb 6, 2026 at sec.gov
RewordedMD&A
Year Ended December 31, 2024 2025 Consolidated Aptar Aptar Aptar Pharma Beauty Closures Corporate & Other Net Interest Pharma Beauty Closures Net Sales $ 3,582,890 3,777,181 $ 1,643,152 1,737,481 $ 1,225,730 1,309,437 $ 714,008 730,263 $ — $ — Reported net income $ 374,178 392,497 Reported income taxes 95,587 98,881 Reported income before income taxes 469,765 447,353 68,797 54,832 (69,420) (31,797) 491,378 461,073 87,523 56,310 (72,467) (41,061) Adjustments:
Read it in 10-K Feb 6, 2026 at sec.gov
RewordedMD&A
The positive impact from foreign currency is mainly due to $2.4 million of foreign exchange losses related to the devaluation of the Argentine peso during the fourth quarter of 2023, while the favorable unfavorable impact on pension expense primarily consists of a $1.9 million gain on pension curtailment for a 2024 facility closure in France.
Read it in 10-K Feb 6, 2026 at sec.gov
RewordedMD&A
Given our current earnings and anticipated future earnings, we believe that there is a reasonable possibility that within the next 12 months, sufficient positive evidence may become available to support the realization of $7.0 allow us to reach a conclusion that $1.0 million to $10.0 $5.0 million of deferred tax assets for which there is currently a corresponding the valuation allowance. allowance will no longer be needed.
Read it in 10-K Feb 6, 2026 at sec.gov
RewordedMD&A
Cash and equivalents increased to $402.4 million at December 31, 2025 from $223.8 million at December 31, 2024 from $223.6 million at December 31, 2023 while total short and long-term interest bearing debt of $1.48 billion at December 31, 2025 increased from $1.03 billion at December 31, 2024 decreased from $1.14 billion at December 31, 2023. 2024.
Read it in 10-K Feb 6, 2026 at sec.gov
RewordedMD&A
Year Ended December 31, 2024 Aptar 2025 Pharma Aptar Beauty Aptar Closures Total Reported Net Sales Growth 8% (3)% 6% 7% 2% 3% 5% Currency Effects (1) —% —% 1% —% (3)% (2)% (1)% (2)% Acquisitions —% (3)% —% —% —% (1)% Core Sales Growth 8% (3)% 3% 3% 2% 1% 2%
Read it in 10-K Feb 6, 2026 at sec.gov
RewordedMD&A
Year Ended December 31, 2024 2025 Food Beverage Personal Care Other (2) Total Reported Net Sales Growth 4% 3% (4)% 2% 7% (8)% 8% 2% Currency Effects (1) 1% 1% 2% 1% 1% (1)% (1)% (1)% (3)% (1)% Acquisitions —% (1)% —% —% —% —% Core Sales Growth 2% 6% (9)% 5% 3% (2)% 3% 3% 1%
Read it in 10-K Feb 6, 2026 at sec.gov
RewordedMD&A
Optimization initiative $ 9,837 $ 13,019 $ 45,445 Prior year initiatives — (17) (441) Total Restructuring Initiatives $ 9,837 $ 13,002 $ 45,004 Restructuring Initiatives by Segment Aptar Pharma $ 1,080 $ 589 $ 4,852 Aptar Beauty 4,469 8,041 20,683 Aptar Closures 3,566 3,835 17,927 Corporate & Other 722 537 1,542 Total Restructuring Initiatives $ 9,837 $ 13,002 $ 45,004
Read it in 10-K Feb 6, 2026 at sec.gov
RewordedMD&A
Personal However, personal care core sales increased 2% as 13% over the prior year on higher sales of our hair care and body and skin care products more than compensated for lower sales of our sun care applications. products.
Read it in 10-K Feb 6, 2026 at sec.gov
Quiet changesMD&A
Our determination of fair value involved judgment and the use of significant estimates and significant assumptions, including assumptions regarding the projected revenue growth rates, projected EBITDA margins, as well as the discount rate to calculate estimated future cash flows.
Read it in 10-K Feb 6, 2026 at sec.gov
Quiet changesMD&A
The allocation of the purchase price utilizes significant estimates and significant assumptions in determining the fair values of identifiable assets acquired and liabilities assumed, especially with respect to intangible assets.
Read it in 10-K Feb 6, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ATR/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.